Delayed linkage to HIV care among refugee late presenters in Montreal, Canada



Centre universitaire **McGill University** de santé McGill Health Centre Institut de recherche **Research Institute**

B. LINTHWAITE¹, M. KLEIN¹, B. LEBOUCHÉ¹, J. COX^{1,2}, C. FRENETTE¹, C. COSTINIUK¹, and N. KRONFLI¹

¹McGill University Health Centre, Montreal, Canada ²Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Introduction

Refugees living with HIV in Canada

- There is an increasing number of refugees living with HIV (RLHIV) in Canada.¹
- In the first half of 2018, Quebec received >50% of all refugees entering Canada, primarily from the United States.^{2,3}
- All refugees undergo an Immigration Medical Examination (IME), which includes mandatory HIV screening with linkage to HIV care facilitated by immigration physicians.⁴
- Health-related costs for all refugees fall under the Interim Federal Health Program (IFHP).⁴

Delayed cART initiation among RLHIV

Baseline sociodemographic and HIV-related characteristics are summarized in Table 1.

Overall, 49% (50/102) of refugees were newly diagnosed in Canada.

Among those <u>newly diagnosed</u>:

Results


- **62% (31/50) were late presenters (**CD4 < 350 cells) and 22% (11/50) presented with advanced HIV (CD4 < 200 cells or an OI);
- 24% (12/50) presented with high-level viremia (VL>100,000 copies/ml); and
- 38% had baseline ARV resistance to at least one drug class.

Among those previously diagnosed outside Canada:

Median times between each step of the HIV care cascade among RLHIV diagnosed in Canada (Fig. 1):

- *Entry into Canada to IME screening:* 30 days [IQR: 14;55];
- *IME screening to notification of diagnosis:* 31 days [IQR: 21;49];
- *Notification to linkage to care:*
- 6 days [IQR: 1.5;18];
- *Linkage to cART prescription:* 11 days [IQR: 5.5;17]; and
- *cART prescription to first undetectable VL:* 46 days [IQR: 29;76].
- Median time from entry into Canada to viral suppression was 152 days [IQR: 126;183].

Figure 1: Median time between HIV care cascade steps



- The consequences of delayed combination antiretroviral (ARV) therapy (cART) include:
 - Higher rates of secondary transmission;⁵ and
 - Increased HIV-related morbidity and mortality.⁶
- These consequences are more pronounced in late presenters (CD4 count < 350 cells/ μ l).^{7,8} Recent European studies suggest that RLHIV are significantly more likely to be late presenters.^{9, 10}

Objectives

We conducted a retrospective chart review of RLHIV referred to the McGill University Health Centre (MUHC) for HIV care to:

- 1) Quantify time to each step in the HIV care cascade from entry into Canada to viral suppression among those newly diagnosed in Canada; and
- Describe baseline sociodemographic and clinical characteristics

Methods Study design

- 31% (16/52) were late presenters and 15% (8/52) had advanced HIV; and
- 31% (16/52) had detectable VLs at presentation.

Overall, 38% of newly diagnosed patients were

linked to HIV care within 30 days, 74% within 60 days and 86% within 90 days from HIV screening.

			Overall	Diagnosed in Canada	Diagnosed outside Canada
			(n=102)	(n=50)	(n=52)
Age (median [IQR])		37 [32; 44]	37 [32; 44]	37 [33; 43]	
Sex Female Male		68 (67%)	27 (54%)	41 (78%)	
		Male	34 (33%)	23 (46%)	11 (21%)
Country of origin	Africa	Nigeria	23 (23%)	9 (18%)	14 (27%)
		Other	32 (31%)	13 (26%)	19 (37%)
	Latin America	Haiti	45 (44%)	28 (56%)	17 (33%)
		Other	2 (2%)	0 (0%)	2 (4%)
CD4 at presentation in Canada, cells/µl		361,	309,	446,	
(median, range, [IQR])		11-1136,	11-811,	14-1136,	
		[229; 407]	[210; 386]	[271; 674]	
	CD4 nadir < 200		19 (19%)	11 (22%)	8 (15%)
CD4 nadir < 350		47 (46%)	31 (62%)	16 (31%)	
Baseline viral load, copies/ml			3857,	29191,	<20,
(median, range, [IQR])			<20 - >1 million, [<20;	<20 -> 1 million,	<20 -> 1 million,
			41368]	[5558; 97534]	[<20; 533]
OI at presentation			1 (1%)	1 (2%)	0 (0%)
Requiring primary prophylaxis		18 (18%)	9 (18%)	9 (17%)	
cART	Single treatment regimens		84 (82%)	41 (82%)	43 (87%)
regimens,	3rd agent:	NNRTI	3 (3%)	0	3 (6%)
most recent		PI	3 (3%)	0	3 (6%)
prescription II			95 (93%)	49 (98%)	46 (88%)

screen 31 days Notification of HIV 124 days diagnosis 6 days Linkage to HIV care 11 days cART prescription

46 days

This is a retrospective, single arm cohort study of adult RLHIV (aged ≥ 18 years) referred to the MUHC for HIV care over a one-year period starting June 1st 2017.

HIV care cascade for RLHIV

We conceptualize the HIV care cascade for RLHIV in Canada as a continuum of HIV care from entry into Canada to viral suppression.¹¹ Among refugees diagnosed with HIV in Canada, we will measure the time (in days) between six steps along the care cascade:

- Entry into Canada;
- ii. IME screening;
- iii. Notification of HIV diagnosis*;
- iv. Linkage to HIV care**;
- First cART prescription in Canada; and
- vi. First undetectable viral load (VL) in Canada.

*Notification of HIV diagnosis: date of referral for HIV care. **Linkage to HIV care: date of the first HIV care visit.

Baseline ARV	Yes	27 (26%)	19 (38%)	8 (15%)	40 days	
resistance	No	34 (33%)	26 (52%)	8 (15%)		
	Unknown	41 (40%)	5 (10%)	36 (69%)		
PPD	Positive	40 (39%)	16 (32%)	24 (46%)		
	Negative	57 (56%)	33 (66%)	24 (46%)	\checkmark	\checkmark
	Not done/missing	5 (5%)	1 (2%)	4 (8%)	· · · · · · · · · · · · · · · · · · ·	
Co-infection with HBV		6 (6%)	4 (8%)	2 (4%)	Viral suppression	
OI = opportunistic infection; $ARV = antiretroviral;IQR = interquartile range;$ $cART = combination ARV therapy;$			<i>NNRTI</i> = non-nucleoside reverse transcriptase inhibitor; <i>PI</i> = protease inhibitor;			

Conclusions

- While the majority (62%) of newly diagnosed refugees were late presenters, only 38% were linked to care within 30 days.
- The most significant delays occurred between entry into Canada and IME screening (median of 30 days), and IME screening and notification of HIV diagnosis (median of 32 days).
- Even in a system with a clear care pathway, there is a need to expedite referrals to HIV care following entry into Canada.
- Further investigations into potential inefficiencies in the IME process should be explored.

References

1) Bourgeois A, Edmunds M, Awan A, Jonah L, Varsaneux O, Siu W. HIV in Canada-Surveillance Report, 2016. Canada communicable disease report= Releve des maladies transmissibles au Canada 2017; 43(12): 248-56.

2) Government of Canada. Asylum Claims. 2018-08-13. https://www.canada.ca/en/immigration-refugees-citizenship/services/refugees/asylum-claims.html (accessed 2018-08-19.

3) Immigration D, et Inclusion Québec, Demandeurs d'asile au Québec. 2018-08-17. https://www.immigration-

quebec.gouv.qc.ca/fr/informations/situation-demandeurs-asile/index.html (accessed 2018-08-19).

4) Government of Canada. Interim Federal Health Program: Summary of coverage. 2018-03-23. https://www.canada.ca/en/immigration-refugeescitizenship/services/refugees/help-within-canada/health-care/interim-federal-health-program/coverage-summary.html (accessed 2018-08-19).

5) Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Jama 2013; 310(15): 1619-20.

6) Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The Lancet infectious diseases 2014; 14(4): 281-90.

7) Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS medicine 2013; 10(9): e1001510.

8) Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV medicine 2011; 12(1): 61-4.

9) Ross J, Cunningham CO, Hanna DB. HIV outcomes among migrants from low-income and middle-income countries living in high-income countries: a review of recent evidence. Current opinion in infectious diseases 2018; 31(1): 25-32.

10) de Coul ELO, Van Sighem A, Brinkman K, et al. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996–2014: results from a national observational cohort. BMJ open 2016; 6(1): e009688.

11) Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS research and therapy 2016; 13(1): 35